EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial–Mesenchymal Transition Metastatic Phenotype

David A Bunsick iD, Jenna Matsukubo iD, Rashelle Aldbai, Leili Baghaie iD, Myron R Szewczuk iD

Cells · 2024

DOI: 10.3390/cells13060480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von David A Bunsick und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada. Hauptthemen laut MEDLINE: Cannabinoids, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada (NSERC) Grant # RGPIN-2020-03869, Natural Sciences and Engineering Research Council of Canada (NSERC), NSERC Alliance COVID-19.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding the role of biased G protein-coupled receptor (GPCR) agonism in receptor signaling may provide novel insights into the opposing effects mediated by cannabinoids, particularly in cancer and cancer metastasis. GPCRs can have more than one active state, a phenomenon called either ‘biased agonism’, ‘functional selectivity’, or ‘ligand-directed signaling’. However, there are increasing arrays of cannabinoid allosteric ligands with different degrees of modulation, called ‘biased modulation’, that can vary dramatically in a probe- and pathway-specific manner, not from simple differences in orthosteric ligand efficacy or stimulus-response coupling. Here, emerging evidence proposes the involvement of CB1 GPCRs in a novel biased GPCR signaling paradigm involving the crosstalk between neuraminidase-1 (Neu-1) and matrix metalloproteinase-9 (MMP-9) in the activation of glycosylated receptors through the modification of the receptor glycosylation state. The study findings highlighted the role of CB1 agonists AM-404, Aravnil, and Olvanil in significantly inducing Neu-1 sialidase activity in a dose-dependent fashion in RAW-Blue, PANC-1, and SW-620 cells. This approach was further substantiated by findings that the neuromedin B receptor inhibitor, BIM-23127, MMP-9 inhibitor, MMP9i, and Neu-1 inhibitor, oseltamivir phosphate, could specifically block CB1 agonist-induced Neu-1 sialidase activity. Additionally, we found that CB1 receptors exist in a multimeric receptor complex with Neu-1 in naïve, unstimulated RAW-Blue, PANC-1, and SW-620 cells. This complex implies a molecular link that regulates the interaction and signaling mechanism among these molecules present on the cell surface. Moreover, the study results demonstrate that CB1 agonists induce NFκB-dependent secretory alkaline phosphatase (SEAP) activity in influencing the expression of epithelial–mesenchymal markers, E-cadherin, and vimentin in SW-620 cells, albeit the impact on E-cadherin expression is less pronounced compared to vimentin. In essence, this innovative research begins to elucidate an entirely new molecular mechanism involving a GPCR signaling paradigm in which cannabinoids, as epigenetic stimuli, may traverse to influence gene expression and contribute to cancer and cancer metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsNeoplasmsCannabinoid Receptor AgonistsMatrix Metalloproteinase 9VimentinLigandsGlycosylationNeuraminidaseReceptors, G-Protein-CoupledEpithelial-Mesenchymal TransitionCadherins

Stichwörter der Autor:innen

CB1 receptorMMP9Neu1PANC-1RAW-blueSEAPSW-620cannabinoid

Substanzen

Cannabinoid Receptor AgonistsMatrix Metalloproteinase 9VimentinLigandsNeuraminidaseReceptors, G-Protein-CoupledCannabinoidsCadherins

Autor:innen und Institutionen

  • Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
  • Faculty of Medicine, University of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, ON K1H 8M5, Canada.

ORCID-Profile: David A Bunsick, Jenna Matsukubo, Leili Baghaie, Myron R Szewczuk

Förderung

  • Natural Sciences and Engineering Research Council of Canada (NSERC) Grant # RGPIN-2020-03869
  • Natural Sciences and Engineering Research Council of Canada (NSERC)
  • NSERC Alliance COVID-19
  • NSERC

Zitieren

APA

Bunsick, D. A., Matsukubo, J., Aldbai, R., Baghaie, L., & Szewczuk, M. R. (2024). Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial–Mesenchymal Transition Metastatic Phenotype. Cells. https://doi.org/10.3390/cells13060480

Vancouver

Bunsick DA, Matsukubo J, Aldbai R, Baghaie L, Szewczuk MR. Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial–Mesenchymal Transition Metastatic Phenotype. Cells. 2024. doi:10.3390/cells13060480

BibTeX
@article{Bunsick2024,
  author = {Bunsick, David A and Matsukubo, Jenna and Aldbai, Rashelle and Baghaie, Leili and Szewczuk, Myron R},
  title = {Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial–Mesenchymal Transition Metastatic Phenotype},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13060480}
}
Kostenlos starten →